Latest news with #BenignProstaticHyperplasia
Hans India
20-05-2025
- Health
- Hans India
Hospital plans centre of education for South Asia
Bengaluru: Fortis Hospitals in Bengaluru signed a Memorandum of Understanding on Monday with Teleflex Incorporated, a global provider of medical technologies, to create UroLift Center of Education for South Asia in India. The UroLift System uses a minimally invasive approach to treating Benign Prostatic Hyperplasia (BPH), stated a press release issued by Fortis Hospitals on Monday. Typically, no catheter is required after the treatment, according to Fortis Hospitals. BPH is a common condition marked by urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life, added the press release. 'Our collaboration with Fortis Hospitals will empower medical professionals with advanced knowledge and hands-on training, ultimately improving patient care,' said Arun Kaushik, Managing Director, South Asia, Teleflex. Dr. Mohan Keshavamurthy, Principal Director of Renal Sciences, Fortis Hospitals in Bengaluru, said, 'Through this collaboration, we are committed to helping Urologists acquire requisite skill to optimise individualised treatment solutions for patients requiring Endoscopic surgical solutions for BPH.' These training programs for the UroLift System will be conducted at Fortis Hospitals, Bannerghatta Road, Bengaluru, he added.
The Hindu
19-05-2025
- Business
- The Hindu
City hospital signs MoU with Teleflex to create a UroLift Center of Education for South Asia
Fortis Hospitals, Bengaluru, recently signed a Memorandum of Understanding (MoU) with Teleflex Incorporated (NYSE: TFX), a global provider of medical technologies to create UroLift Center of Education for South Asia in India. The UroLiftTM System uses a minimally invasive approach to treating Benign Prostatic Hyperplasia (BPH). BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life. 'The UroLiftTM System is a BPH procedure that does not require heating, cutting, removal, or destruction of prostate tissue. The UroLiftTM System provides rapid symptom relief and preserves sexual function. Typically, no catheter is required after the treatment,' said the press release. 'Our collaboration with Fortis Hospitals will empower medical professionals with advanced knowledge and hands-on training, ultimately improving patient care,' said Arun Kaushik, Managing Director, South Asia, Teleflex. Dr. Mohan Keshavamurthy, Principal Director – Renal Sciences, Fortis Hospitals, Bengaluru, said, 'Through this collaboration, we are committed to helping Urologists acquire requisite skill to optimise individualised treatment solutions such as UROLIFT for patients requiring Endoscopic surgical solutions for BPH and enhancing outcomes thereof. The programme is designed to provide a comprehensive training program to Urologists to ensure careful selection and safe delivery of the UroLift System to patients in their practice.'
Time of India
04-05-2025
- Health
- Time of India
Prostate health
Lalit Kapoor is a 1971 graduate from IIT Kanpur and has done his MBA from UCLA. Lalit is a successful serial entrepreneur in Silicon Valley. With age, he developed lifestyle diseases and decided to reverse them by changing diet and lifestyle. This led him to study and research in the field of nutrition and plant-based whole food field. Eventually, he successfully got rid of all his chronic diseases and reinvented himself. Lalit became an inspiration for his IIT-K batch mates and started to guide them with his learnings. Many of them benefitted and successfully reversed their chronic diseases. He further incorporated the Nobel prize winning work by Nobel laureates Dr Yoshinori Ohsumi (2016) on autophagy, Dr Jeffery Hall (2017) on circadian rhythm and Dr Tasuko Honzo (2018) on immunotherapy into his recommendations. He has conducted over 450 course sessions which have been attended by over 150,000 people in over 50 countries with thousands of success stories. He runs over 100 active social groups and his NGO 'Plant Based Wellness Foundation' has over 40 centers worldwide. Lalit has also taught a course as a visiting faculty on Nutrition & Health at IIT Kanpur for one semester. LESS ... MORE Prostate health is a subject relevant to all men over the age of 45. My focus will be on a condition known as Benign Prostatic Hyperplasia (BPH), a common condition among aging men. If you want a rough estimate of your likelihood of being affected, just add a percentage sign to your age—60% of men over 60, 70% over 70, and so on. Understanding the basics The human body is constantly detoxifying itself, with waste products filtered out by the kidneys. Urine collects in the bladder, which has a capacity of around 400–500 ml. When it's full, stretch receptors trigger the urge to urinate. The bladder connects to the penis via the urethra, and surrounding the urethra just below the bladder is a small, walnut-sized gland called the prostate, weighing about 20 grams. This gland produces seminal fluid, which mixes with sperm from the testicles during ejaculation. Early signs of BPH The earliest sign of prostate enlargement is nocturia—waking up at night to urinate. While younger men typically sleep through the night, if you're getting up even once, it may indicate prostate growth. Another common sign is incomplete bladder emptying. If you urinate, pause, and then feel the need to go again shortly after, your prostate may be enlarged and obstructing urine flow. What Causes BPH? The exact cause of BPH is still unknown. Some research suggests a potential link to dairy consumption, but the mechanism remains unclear. Here are some of the risk factors associated with prostate growth: According to Mayo Clinic, obesity among men can increase the risk of BPH. Zinc deficiency (which may be helped by consuming pumpkin and sesame seeds). Dietary deficiency in Omega-3 intake is another risk factor. I recommend that flaxseeds, chia seeds or hemp seeds should be consumed regularly. Salmon is a rich source of omega-3 and Zinc so if you are going to consume some animal food, salmon may be your least harmful bet. How BPH Affects urine action The main issue with an enlarged prostate is the obstruction of urine flow, either from the enlarged gland or from weakened urethral walls. The urethra is lined with epithelial cells, which can be weakened by poor nutrition and exposure to toxins from ultra-processed foods. Short-chain fatty acids (SCFAs)—produced by gut bacteria digesting dietary fiber—help strengthen these epithelial cells. Diets low in fiber and high in chemicals (even those deemed 'Generally Recognised as Safe' or GRAS) can contribute to urinary issues. It is for this reason I advise against consuming ultra-processed foods. After age 40–45, the prostate typically starts enlarging and may reach 100 grams or more, putting pressure on the urethra. The pressure with which we urinate goes down. In addition with age other symptoms begin to show up such as: Terminal dripping: After urination has ended, a few drops persist. Hesitancy: Before you can start urinating, it takes some time for flow to begin. Incomplete emptying: A feeling that you have not completely emptied the bladder. As these things happen when the bladder needs to work harder to compensate for obstruction in the urethra. The frequency of urination increases, the sense of urgency also sets in, nocturia also develops and you start going to bathroom during the night; starting with once and then slowly frequency increases to 4-5 times. Whatever I have discussed so far is commonly called normal behavior. Most men expect it as a part of aging process. It is at this stage that complications begin to arise. Some of these complications include: Infections in stored urine causing a burning sensation during urination Crystal formations in stored urine which combine to form stones in the kidney or bladder. Stones can also block the urethra. Chronic Urinary Retention: The normal bladder size is 500ml. +/- 100ml. Under chronic urinary retention, it can double, triple, or even quadruple. This can lead to a problem of incontinence and also affect the kidneys. Acute Urinary Retention: The worst problem is when one finds that one morning they are unable to urinate and need to be taken to the emergency room. I have intentionally not covered other serious prostate problems like prostatitis and prostate cancer for which you need to see a Urologist. The good news If you're following a plant-based whole-food (PBWF) diet, practicing intermittent fasting, and are physically active (walking 10,000 steps or more a day), you may already be protecting your prostate health. Many of my health group members, including myself, have experienced significant improvement—my nocturia episodes decreased from 4–5 times a night at age 63 to just once per night. Treatment and prevention strategies My experience with hundreds of patients suggests that a plant-based, whole food diet rich in Omega-3s (flax, chia, hemp seeds and walnuts) helps reduce symptoms of BPH. Pumpkin seeds have long been used to support urinary and prostate health. Interestingly, deep-sea divers are known to consume them regularly for this very reason. Recent studies highlight two key benefits of pumpkin seed consumption on urinary flow: Reduced urgency and improved emptying: After consuming meals or beverages with diuretic effects, men who take pumpkin seeds report fewer urgent trips to the bathroom and more complete bladder emptying. Strengthened urethral function: Daily intake of pumpkin seeds has been shown to strengthen the walls of the urethra, improving urinary flow metrics by over 20%. Other helpful approaches include: Nuts (almonds, cashews, peanuts, pine nuts) are high in zinc, which has anti-inflammatory properties. Green tea and cranberry juice: Both have shown potential benefits for the prostate. Cruciferous vegetables, berries, tomatoes, and green tea—all rich in antioxidants and anti-inflammatory compounds. Two small studies have found some theoretical evidence that bananas may reduce symptoms caused by prostate growth. The evidence suggests that one cause of prostate growth is dairy. So all dairy products must be avoided. Regular physical activity is very important for prostate sufferers. Walking, jogging, bicycling, swimming, dancing and yoga are all good activities. The '5-second exercise' often mentioned in relation to prostate health is a type of Kegel exercise. This exercise involves contracting and holding the pelvic floor muscles for five seconds, then relaxing them. Kegel exercises can help strengthen these muscles, which support the bladder, bowel, and prostate. The research also suggests that engagement in regular sex seems to help with prostate problems greatly. To manage symptoms of an enlarged prostate one should avoid drinks that can irritate the bladder and increase urination. These include coffee, black tea, soft drinks, beer, wine, whiskey, energy drinks, sweetened fruit juices, milkshakes, and alcoholic cocktails. Please watch the linked videos on the subject. Prostate health Prostate Health: 5 tips to help prevent an enlarged prostate Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Yahoo
17-02-2025
- Health
- Yahoo
Benign Prostatic Hyperplasia Surgical Treatment Market to Hit USD 17.19 Billion by 2030 with 5.3% CAGR
DELRAY BEACH, Fla., Feb. 17, 2025 /PRNewswire/ -- The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in 2024 and an impressive US$17.19 billion by 2030. Benign prostatic hyperplasia is a condition in males in which the prostate is enlarged, leading to difficulty in urinating. The growing incidence of benign prostatic hyperplasia (BPH) cases is expected to drive the demand for Benign Prostatic Hyperplasia Surgical Treatment. The aging population is a global demographic trend characterized by an increasing proportion of older individuals due to longer life expectancy and declining birth rates. The rising incidence of obesity in males is also expected to increase the incidence of BPH as the two factors are closely associated. Obesity leads to several issues, such as rising sympathetic nervous activity, altered endocrine status, increased intra-abdominal pressure, increased inflammation process, and oxidative stress, favorable conditions for developing BPH. However, the growing preference for minimally invasive surgeries is considered adequate, providing reduced recovery times and fewer complications compared to traditional surgery. Additionally, the high growth potential of emerging economies, along with the favorable funding investments for BPH drug development, are expected to provide lucrative growth opportunities for market players. Download PDF Brochure: Browse in-depth TOC on "Benign Prostatic Hyperplasia Surgical Treatment Market" 368 - Tables59 - Figures328 - Pages Based on drug type, the global Benign Prostatic Hyperplasia Surgical Treatment market can be divided into three segments: alpha-blockers (α-blockers), 5-alpha reductase inhibitors (5-ARIs), and other drug types [combination drugs, muscarinic receptor antagonists (MRAs), and phosphodiesterase 5 (PDE5) inhibitors]. The alpha-blockers (α-blockers) category is expected to have the highest CAGR from 2024 to 2030. Factors driving the growth of alpha-blockers (α-blockers), include an aging population. Alpha-blockers (α-blockers) are recommended as first-line treatment for BPH as it relax the smooth muscle of the prostate and bladder neck to improve urine flow and reduce bladder outlet obstruction. These are highly efficient drugs, such as monotherapy, in treating BPH-associated lower urinary tract symptoms (LUTS). The Benign Prostatic Hyperplasia Surgical Treatment market, by type, is segmented into Transurethral Resection of the Prostate (TURP), Laser Surgery, UroLift Procedure, Rezūm Procedure, Robot-assisted Waterjet Ablation, Prostatic Stenting, Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Prostatic Arterial Embolization (PAE) and Other Procedures. The Transurethral Resection of the Prostate (TURP) segment is anticipated to witness the highest growth rate during the forecast period. This is because TURP, a well-established and cost-effective first-line preferred treatment procedure, is often covered by insurance and is typically less expensive than newer options regarding the procedure and hospital stay. Based on therapy, the Benign Prostatic Hyperplasia Surgical Treatment market is segmented into monotherapy and combination drug therapy. In the upcoming years, monotherapy is expected to grow at the fastest rate because to the rising prevalence BPH patients, cost efficiency, and convenience in treating BPH. Low risk of side effects and drug interactions, significantly improving the quality of life. Based on the type of end-user, the Benign Prostatic Hyperplasia Surgical Treatment market is divided into hospitals, ambulatory surgery centers & clinics, and home care setting. Between 2024 and 2030, the home care setting segment is predicted to expand at the fastest rate. The growth rate of the home care setting segment can be attributed to the large patient population of individuals being administered medication in the convenience and efficiency of indoor settings. Medications like alpha-blockers or 5-alpha reductase inhibitors can be taken orally, contributing to market growth. The global Benign Prostatic Hyperplasia Surgical Treatment market has been segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. The Asia Pacific region is expected to witness the highest growth rate during the forecast period. North America is the largest regional market for BPH treatment. The North American market comprises the US and Canada. The rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market. The large share of the US in the North American BPH treatment market can be mainly attributed to the growing target population, the high incidence of BPH, and the strong presence of medical device manufacturers. Additionally, favorable reimbursement policies, high disposable incomes, a strong and improved healthcare infrastructure, research funding, and product launches. The US has a strong healthcare system with advanced infrastructure. The robust healthcare infrastructure, combined with specialized healthcare facilities and a rising number of hospitals which drives the Benign Prostatic Hyperplasia Surgical Treatment market in the country. The growing geriatric population along with an increasing number of BPH cases is supporting the Benign Prostatic Hyperplasia Surgical Treatment market growth. The funding supports the development of cutting—edge technologies like Robotic waterjet assistance which are increasingly shaping the BPH treatment landscape. For instance, Zenflow, Inc., a US-based medical device company that is developing a minimally invasive treatment for urinary obstruction caused by, benign prostatic hyperplasia announced that it has closed a USD 24 million Series C financing round. The round includes new investor Cook Medical as well as existing investors Indus Opportunities, F-Prime Capital, Medical Technology Venture Partners, and others. Request Sample Pages : The Benign Prostatic Hyperplasia Surgical Treatment market is consolidated, with top companies holding significant market shares. The top three players in the drug type market include GlaxoSmithKline PLC (UK) Astellas Pharma Inc. (Japan) and Viatris Inc. (US. Also, the top three players in the type of market includes Teleflex Incorporated (US), Boston Scientific Corporation (US), and Olympus Corporation (Japan) dominating the market. Players in this market are focusing on adopting organic and inorganic growth strategies such as product approvals, acquisitions, agreements, partnerships, and other developments such as regulatory approvals to increase their BPH treatment products portfolio, cater to customer needs, increase their profitability and expand their presence in the global Benign Prostatic Hyperplasia Surgical Treatment market. By Drug Type Viatris Inc. (US) is the leading player contributing a share of 10-12% in 2023 in the Benign Prostatic Hyperplasia Surgical Treatment Market The company offers 1,400 approved molecules of various therapeutic areas which includes key brands and generics recognized globally. The brand division caters to the BPH surgical products market, i.e., Apha1 adrenergic antagonist known as CARDURA (doxazosin). GlaxoSmithKline PLC (UK) is the second leading Benign Prostatic Hyperplasia Surgical Treatment market player, with a 6.0-8.0% share in 2023. The Commercial Operations segment has three product groups: Vaccines, Specialty Medicines, and General Medicines. The company offers various products to treat chronic & acute diseases. The products for BHP treatment are provided through its General Medicines product group under the Commercial Operations segment. The company offers 5-Alpha-Reductase Inhibitors by the brand name Avodart and a combination drug with dutasteride 500 µg and 400 µg tamsulosin hydrochloride by the brand name Duodart. In July 2023, GlaxoSmithKline PLC and Recordati entered into an agreement with GSK to commercialize Avodart (dutasteride) and Combodart/Duodart (dutasteride/tamsulosin) across 21 countries, mainly in Europe, excluding only those where GSK already has a distribution agreement in place. Astellas Pharma Inc. (Japan) In the Benign Prostatic Hyperplasia Surgical Treatment market the company accounts for a share of around 4-6% in 2023. Pharmaceutical products are manufactured and marketed by a single business segment. Th key segments targeted are immunology, anti-infectives, oncology, urology, and metabolic applications. The company provides alpha blocker Harnal (Tamsulosin hydrochloride) for the treatment BPH by the Urology category. The company have a global presence in around 40 countries across the world. By Type Boston Scientific Corporation (US) is the leading Benign Prostatic Hyperplasia Surgical Treatment market player, with a share of 9.0-10.0% in 2023. The various procedures offered by the company include Greenlight XPS Laser System, Moxy Fiber, and Rezum Systems for treating BPH. Teleflex Incorporated (US) is ranked as the second leading player in the Benign Prostatic Hyperplasia Surgical Treatment market. In 2023, The company is contributing a share of 8.0-9.0% in 2023. The Interventional Urology segment offers the UroLift System which is a minimally invasive technology benign prostatic hyperplasia. The company has also introduced the UroLift system in China to make notable progress in advancing other high-growth products and line extensions through the regulatory process. Olympus Corporation (Japan) accounted for a share of 8.0% in 2023 in the Benign Prostatic Hyperplasia Surgical Treatment market. The underlying high-frequency technology of PLASMA has been used for over 17 years. It offers proven therapy for patients with benign prostatic hyperplasia (BPH) and expanded reimbursement for differentiated MIS BPH devices, which provide better clinical outcomes and elevate the standard of care. COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 We have selected six market vendors based on their capabilities, innovations, product offerings, and business strategies. A comprehensive list of all the vendors in this market was created through a product mapping strategy and MarketsandMarkets analysis. Our selected vendor mix includes companies from Tier 1–Tier 4 to cover the Benign Prostatic Hyperplasia Surgical Treatment market. Based on their performance in each criterion, the vendors are divided into four categories: Stars, Emerging Leaders, Omnipresent Players, and Participants. For more information, Inquire Now! Related Reports: Overactive Bladder Treatment Market Urology Devices Market Minimally Invasive Surgical Instruments Market Endoscopy Equipment Market Hemodialysis and Peritoneal Dialysis Market Get access to the latest updates on Benign Prostatic Hyperplasia Surgical Treatment Companies and Benign Prostatic Hyperplasia Surgical Treatment Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
